The phase I/II ILLUMINATE-204 multi-centre study evaluated intra-tumoural TLR-9 agonist (tilsotolimod) therapy in combination with Ipilimumab in PD-1 refractory metastatic melanoma (NCT02644967). This evidence concerns the gene PDCD1 and metastatic melanoma.